Medicinal chemistry is discipline at the intersection of chemistry, especially synthetic organic chemistry, and pharmacology and various other biological specialties, where they are involved with design, chemical synthesis and development for market of pharmaceutical agents, or bio-active molecules (drugs).Compounds used as medicines are most often organic compounds, which are often divided into the broad classes of small organic molecules (e.g., atorvastatin, fluticasone, clopidogrel) and "biologics" (infliximab, erythropoietin, insulin glargine), the latter of which are most often medicinal preparations of proteins (natural and recombinant antibodies, hormones etc.). Inorganic and organometallic compounds are also useful as drugs (e.g., lithium and platinum-based agents such as lithium carbonate and cisplatin as well as gallium).In particular, medicinal chemistry in its most common practice—focusing on small organic molecules—encompasses synthetic organic chemistry and aspects of natural products and computational chemistry in close combination with chemical biology, enzymology and structural biology, together aiming at the discovery and development of new therapeutic agents. Practically speaking, it involves chemical aspects of identification, and then systematic, thorough synthetic alteration of new chemical entities to make them suitable for therapeutic use. It includes synthetic and computational aspects of the study of existing drugs and agents in development in relation to their bioactivities (biological activities and properties), i.e., understanding their structure–activity relationships (SAR). Pharmaceutical chemistry is focused on quality aspects of medicines and aims to assure fitness for purpose of medicinal products.
Sample Chapter(s)
Preface (51 KB)
Components of the Book:
- Chapter1
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes
- Chapter2
Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs
- Chapter3
X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design
- Chapter4
The Essential Medicinal Chemistry of Curcumin: Miniperspective
- Chapter5
The application of click chemistry in the synthesis of agents with anticancer activity
- Chapter6
Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis
- Chapter7
Matched molecular pair-based data sets for computer-aided medicinal chemistry
- Chapter8
Follow up: Compound data sets and software tools for chemoinformatics and medicinal chemistry applications: update and data transfer
- Chapter9
Medicinal Chemistry of Competitive Kainate Receptor Antagonists
- Chapter10
Pharmacokinetics-Driven Evaluation of the Antioxidant Activity of Curcuminoids and Their Major Reduced Metabolites—A Medicinal Chemistry Approach
- Chapter11
Recent developments in the medicinal chemistry of single boron atom-containing compounds
- Chapter12
Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications
- Chapter13
Design, synthesis, in vitro and in vivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer’s disease
- Chapter14
Design, Synthesis, Characterization and in vivo Antidiabetic Activity Evaluation of Some Chalcone Derivatives
- Chapter15
Synthesis, X-ray structure, in silico calculation, and carbonic anhydrase inhibitory properties of benzylimidazole metal complexes
Readership:
Students, academics, teachers and other people attending or interested in Medicinal Chemistry
|
|
|
Chapter1
Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes
PDF (3500 KB)
|
|
|
|
|
|
|
Chapter2
Selective Inhibitors of Protozoan Protein N-myristoyltransferases as Starting Points for Tropical Disease Medicinal Chemistry Programs
PDF (11196 KB)
|
|
|
|
|
|
|
Chapter3
X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design
PDF (1720 KB)
|
|
|
|
|
|
|
Chapter4
The Essential Medicinal Chemistry of Curcumin: Miniperspective
PDF (0 KB)
|
|
|
|
|
|
|
Chapter5
The application of click chemistry in the synthesis of agents with anticancer activity
PDF (0 KB)
|
|
|
|
|
|
|
Chapter6
Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis
PDF (0 KB)
|
|
|
|
|
|
|
Chapter7
Matched molecular pair-based data sets for computer-aided medicinal chemistry
PDF (0 KB)
|
|
|
|
|
|
|
Chapter8
Follow up: Compound data sets and software tools for chemoinformatics and medicinal chemistry applications: update and data transfer
PDF (0 KB)
|
|
|
|
|
|
|
Chapter9
Medicinal Chemistry of Competitive Kainate Receptor Antagonists
PDF (0 KB)
|
|
|
|
|
|
|
Chapter10
Pharmacokinetics-Driven Evaluation of the Antioxidant Activity of Curcuminoids and Their Major Reduced Metabolites—A Medicinal Chemistry Approach
PDF (0 KB)
|
|
|
|
|
|
|
Chapter11
Recent developments in the medicinal chemistry of single boron atom-containing compounds
PDF (0 KB)
|
|
|
|
|
|
|
Chapter12
Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications
PDF (0 KB)
|
|
|
|
|
|
|
Chapter13
Design, synthesis, in vitro and in vivo evaluation of benzylpiperidine-linked 1,3-dimethylbenzimidazolinones as cholinesterase inhibitors against Alzheimer’s disease
PDF (0 KB)
|
|
|
|
|
|
|
Chapter14
Design, Synthesis, Characterization and in vivo Antidiabetic Activity Evaluation of Some Chalcone Derivatives
PDF (0 KB)
|
|
|
|
|
|
|
Chapter15
Synthesis, X-ray structure, in silico calculation, and carbonic anhydrase inhibitory properties of benzylimidazole metal complexes
PDF (0 KB)
|
|
|
|
Andrew S. Bell
Andrew S. Bell
Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development, Kent, United Kingdom
Gareth P. Williams
Gareth P. Williams
High Throughput Screening Center of Emphasis, Pfizer Worldwide Research and Development, Kent, United Kingdom
Tanya Parkinson
Tanya Parkinson
Opportunities for Partnership in Medicine, Pfizer Worldwide Research and Development, Kent, United Kingdom
Robin J. Leatherbarrow
Robin J. Leatherbarrow
Institute of Chemical Biology, Department of Chemistry, Imperial College, London, United Kingdom
Anthony A. Holder
Anthony A. Holder
Division of Parasitology, Medical Research Council National Institute for Medical Research, London, United Kingdom
and more...